产前治疗先天性肺腺瘤样畸形中皮质类固醇的应用：综合评价。

Use of Corticosteroids in Prenatal Treatment of Congenital Pulmonary Adenomatoid Malformation: Integrative Review.

机构信息

Fetal Medicine Program, Department of Gynecology and Obstetrics, Women's Hospital, University of Campinas, Campinas, SP, Brazil.

出版信息

Rev Bras Ginecol Obstet. 2022 Mar;44(3):304-310. doi: 10.1055/s-0041-1741517. Epub 2022 Feb 2.

DOI:10.1055/s-0041-1741517

PMID:35108733

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9948104/

Abstract

OBJECTIVE

To review data on the use of corticosteroids for the treatment of fetuses with high-risk congenital pulmonary adenomatoid malformation (CPAM).

METHODS

Integrative review based on the literature available on MEDLINE and LILACS, including articles published until November, 2020.

RESULTS

The initial search resulted in 87 articles, 4 of which were selected for analysis, with all of them being retrospective descriptive observational studies. In the group of fetuses that received only a single corticosteroid cycle, the hydrops resolution rate was 70%, and the survival rate was 83.8%. In fetuses treated with 2 or more cycles of corticosteroids, there was an improvement in the condition of hydrops or edema in a single body compartment in 47%, and survival of 81.8% of the fetuses.

CONCLUSION

The use of corticosteroids for the prenatal treatment of high-risk CPAM appears to be associated with an improvement in perinatal outcomes.

摘要

目的

回顾使用皮质类固醇治疗高危先天性肺腺瘤样畸形（CPAM）胎儿的数据。

方法

基于 MEDLINE 和 LILACS 上可用的文献进行综合回顾，包括截至 2020 年 11 月发表的文章。

结果

最初的搜索结果产生了 87 篇文章，其中 4 篇被选入进行分析，所有文章都是回顾性描述性观察研究。在仅接受一个皮质类固醇周期治疗的胎儿组中，水肿消退率为 70%，存活率为 83.8%。在接受 2 个或更多皮质类固醇周期治疗的胎儿中，有 47%的胎儿单一体腔的水肿或肿胀状况得到改善，81.8%的胎儿存活。